Reinke, Britta
Mahlke, Candelaria
Botros, Christina
Kläring, Alexa
Lambert, Martin
Karow, Anne
Gallinat, Jürgen
Zapf, Antonia
Ozga, Ann-Kathrin
Höller, Alexandra
Bustami, Nadia
Reimer, Jens
Lüdtke, Jenny
Schaper, Oliver
Lison, Martin
Bechdolf, Andreas
Baumgardt, Johanna
Spiegel, Jennifer
Hardt, Olaf
Rout, Sandeep
Memarzadeh, Sonja
von Peter, Sebastian
Schwarz, Julian
Langer, Claudia
Glotz, Sabine
Frasch, Karel
Rüsch, Nicolas
Künstler, Ulf
Bock, Thomas
Becker, Thomas
Funding for this research was provided by:
Volkswagen Foundation (Az.: 94 206)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 24 June 2022
Accepted: 7 September 2022
First Online: 19 September 2022
Declarations
:
: The ethics committee of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, gave full approval to the HoPe trial on January 2nd, 2020 (LPEK-0096). Ethics committees of all study sites followed this approval. Study participants are informed about the trial in detail and extensively. Written informed consent is obtained from all participants at recruitment.All personal data assessed in the trial is subject to medical confidentiality. The data protection officer of the University Medical Center Hamburg-Eppendorf granted full approval to the data assurance concept of the HoPe trial. The HoPe trial is filed in the directory of processing activity at the legal division (under the number 01–198), dated July 1st, 2020. The data protection officers of all study sites followed this approval. The data assurance is subject to the provisions of the European General Data Protection Regulation (GDPR), the German Federal Data Protection Act (BDSG), and the Social Security Law Book (SGB).
: Not applicable – there are no individual person’s data or case reports included in the manuscript. All authors approved and gave their consent to publish.
: There were no competing interests declared by any of the authors.